N-803
ImmunityBio
['bladder', 'pivotal', 'immunitybio']
today at , dr. karim chamie, will be presenting the final clinical results of our pivotal trial of il-15r fc superagonist n-803 with bcg in bcg-unresponsive cis and papillary non-muscle-invasive bladder cancer (abstract #4508) at 5:09 pm cdt. #asco22 
ImmunityBio is developing cell and immunotherapy products that are designed to help strengthen each patient’s natural immune system.